FDA's Shocking Quick Review: 3 Psychedelic Trials Could Change Lives Forever—Are You Ready?

The Food and Drug Administration (FDA) announced on Friday that it will expedite the review of three experimental psychedelic drugs aimed at treating major depression and post-traumatic stress disorder (PTSD). This decision marks a notable shift in the regulatory landscape surrounding psychedelic therapies and comes on the heels of recent developments concerning medical marijuana regulations.

Among those receiving expedited reviews is the UK-based biotech firm Compass Pathways, which reported that its synthetic form of psilocybin is being considered for treatment-resistant depression. The company cited positive outcomes from two large Phase 3 studies that have generated encouraging data.

Usona Institute, based in Wisconsin, also received a priority voucher for its psilocybin research related to major depressive disorder. A spokesperson for Usona indicated that they expect the review process to take one to two months after their application is submitted, emphasizing that the voucher merely accelerates the timeline without altering scientific or regulatory standards.

Separately, Transcend Therapeutics, a New York-based company, has been granted a priority review voucher for its methylone treatment targeting PTSD. While the company has not yet confirmed this information to NBC News, they previously announced having obtained "Breakthrough Therapy designation" for their product.

In a broader context, this decision aligns with a recent executive order signed by former President Donald Trump, aimed at promoting U.S.-led research into psychedelics. The FDA's expedited review program, initiated in June 2022, is designed to accelerate the approval process for drugs that are considered urgently needed, potentially reducing the time required for FDA approval from a year to just a few months.

However, critics argue that this program was established without congressional input and could undermine trust in the FDA's regulatory processes. The concern is that pharmaceutical companies may exert undue influence through financial contributions to secure these vouchers.

Historically, the pathway to approval for psychedelic drugs has been fraught with challenges. In 2024, for example, the FDA rejected MDMA—commonly known as ecstasy—for treating PTSD, despite significant advocacy from veterans groups. The FDA determined that there was insufficient evidence to establish the drug’s safety and effectiveness, citing serious concerns about research integrity and potential health risks.

The recent push for increased research into psychedelic therapies has been notably championed by veterans, many of whom suffer from mental health issues stemming from their service. Marty Makary, the FDA Commissioner, highlighted the urgency of addressing these mental health challenges, stating, "When you see something that looks promising for a community that is suffering with mental health illness, despair, and suicidal ideation, you can’t help but recognize that."

The FDA’s action also allows researchers to investigate a form of ibogaine for the first time in the U.S. Miami-based DemeRx NB will explore the potential of noribogaine hydrochloride as a treatment for alcohol use disorder. According to the National Institute on Alcohol Abuse and Alcoholism, nearly 28 million Americans—approximately 1 in 10—struggle with this condition. Importantly, noribogaine is reported to not induce the intense, disruptive experiences associated with ibogaine.

As discussions around psychedelic research intensify, experts stress the importance of rigorous scientific scrutiny. Dr. Peg Nopoulos, chair of the psychiatry department at the University of Iowa, welcomed the regulatory changes but emphasized the need for thorough understanding. "The science behind it has to be rock-solid," she asserted. "Psychedelics are powerful drugs. I’ve seen them save lives. However, we cannot approve a drug without understanding who benefits and the associated risks."

This evolving scenario highlights a significant moment in American healthcare, where potential breakthroughs in mental health treatment are being explored. As the FDA moves forward with these reviews, the implications for patients—a population grappling with pressing mental health challenges—may be profound.